VistaPharm

Executive Summary

VistaPharm, a US-based generic pharmaceutical company founded in 1998 and now a subsidiary of PAI Pharma, specializes in medications for substance use disorder (SUD). The company provides high-quality generic addiction treatment drugs to hospitals, retail pharmacies, and treatment centers, positioning itself as a reliable partner in combating the SUD epidemic and associated stigma. As a private entity, VistaPharm's financials and pipeline details are not publicly disclosed, but its focus on the growing demand for SUD treatments—driven by the opioid crisis and increasing awareness of addiction as a chronic condition—offers a stable market opportunity. The company's long-standing presence and niche specialization suggest a resilient business model, though its dependence on the generic market exposes it to pricing pressures and competition. Overall, VistaPharm appears well-positioned to continue serving a critical healthcare need, but its private nature limits visibility into near-term growth drivers.

Upcoming Catalysts (preview)

• H2 2026FDA Approval of a New Generic SUD Medication70% success
• 2027Expansion of Manufacturing Capacity or Facility50% success
• 2026Strategic Partnership or Distribution Agreement with Major Hospital Network55% success